cycloastragenol has been researched along with Fatty Liver, Nonalcoholic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, S; Gu, M; Huang, C; Huang, J; Ji, G; Li, Y; Tong, Q; Wang, Y; Yang, L; Zhang, S; Zhao, Y | 1 |
1 other study(ies) available for cycloastragenol and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling.
Topics: Animals; Drugs, Chinese Herbal; Female; Hep G2 Cells; Humans; Liver; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Sapogenins; Signal Transduction | 2017 |